Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer
نویسندگان
چکیده
منابع مشابه
Treatment of recurrent epithelial ovarian cancer
Epidemiologic analysis reveals that the mortality rate from ovarian cancer is continuously decreasing due to the improvement of surgery and chemotherapy. However, the prognosis of ovarian cancer patients is still unsatisfactory overall considering that only 30% of patients are alive after five years. In fact, although surgery and first-line systemic chemotherapy induces complete and partial res...
متن کاملTCRM-4317-Treatment of recurrent epithelial ovarian cancer
Correspondence: Sandro Pignata Divisione di Oncologia Medica, Dipartimento Uro-Ginecologico, istituto Nazionale Tumori, via M. Semmola, 80131 – Napoli – italy Tel +39 81 590 3637 Fax +39 81 590 3861 email [email protected] Abstract: Epidemiologic analysis reveals that the mortality rate from ovarian cancer is continuously decreasing due to the improvement of surgery and chemot...
متن کاملRecurrent epithelial ovarian cancer: an update on treatment.
An estimated 85% of patients with epithelial ovarian cancer who achieve a full remission following first-line therapy will develop recurrent disease. Although each subsequent line of therapy is characterized by shorter disease-free intervals, median survival for these patients ranges from 12 months to 24 months. Emerging therapies in the management of ovarian cancer have resulted in a shift in ...
متن کاملYin yang 1 modulates taxane response in epithelial ovarian cancer.
Survival of ovarian cancer patients is largely dictated by their response to chemotherapy, which depends on underlying molecular features of the malignancy. We previously identified YIN YANG 1 (YY1) as a gene whose expression is positively correlated with ovarian cancer survival. Herein, we investigated the mechanistic basis of this association. Epigenetic and genetic characteristics of YY1 in ...
متن کاملA retrospective evaluation of activity of gemcitabine/platinum regimens in the treatment of recurrent ovarian cancer
Background While many of these agents have been compared in prospective clinical trials, the gemcitabine/platinumbased regimens have not been compared in a prospective, randomized clinical trial. While bothgemcitabine/carboplatin and gemcitabine/cisplatin have a similar ORR in separate clinical trials, the tworegimens have never been directly been compared. With overlapping dose-limiting toxici...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cochrane Database of Systematic Reviews
سال: 2018
ISSN: 1465-1858
DOI: 10.1002/14651858.cd008766.pub2